<DOC>
	<DOCNO>NCT00078611</DOCNO>
	<brief_summary>The purpose trial evaluate natalizumab individual moderately severely active Crohn 's Disease .</brief_summary>
	<brief_title>A Clinical Trial Natalizumab Individuals With Moderately Severely Active Crohn 's Disease</brief_title>
	<detailed_description>Natalizumab humanize monoclonal antibody currently investigate potential treatment Crohn 's disease . It believe work prevent white blood cell move blood stream bowel tissue . These cell think cause damage bowel , lead symptom Crohn 's disease . Elan Pharmaceuticals currently sponsor international study evaluate safety efficacy natalizumab individual moderately severely active Crohn 's disease . Individuals Crohn 's disease randomly assign receive either placebo ( inactive solution ) natalizumab intravenous infusion ( mean put directly vein arm ) . There one two chance receive natalizumab one two chance receive placebo . Participants study receive several infusion natalizumab placebo 4-week interval . Eligible participant opportunity enroll extension study allow participant receive natalizumab . For patient enroll extension study , total participation study last approximately 22 week .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Males females 18 year age old Diagnosis Crohn 's disease least 6 month Females must pregnant breastfeeding Must previously take natalizumab Use Crohn 's disease medication permit , closely supervise</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Crohn 's disease</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>IBD</keyword>
	<keyword>Gastroenterology</keyword>
	<keyword>Regional Enteritis</keyword>
	<keyword>Colitis</keyword>
</DOC>